沙库巴曲缬沙坦钠对不同病程慢性心衰伴高血压患者及心室重构的影响研究

Study on the effect of Shakubaqu Valsartan sodium on chronic heart failure with hypertension and ventricular remodeling in patients with different courses of disease

目的:研究沙库巴曲缬沙坦钠对不同病程慢性心衰伴高血压患者及心室重构的影响。方法:前瞻性选取2021年10月―2022年10月收治的128例我院收治的慢性心衰伴高血压患者,按照病程长短的不同分为长病程组和短病程组,各64例。长病程组为慢性心衰伴高血压患者病程在3年以上者;短病程组为慢性心衰伴高血压患者病程在3年及以下者。两组患者均给予沙库巴曲缬沙坦钠治疗。比较两组患者的临床效果,治疗前和治疗后的心室重构及生活质量,随访12个月的无事件生存状况。结果:短病程组(98.44%)较长病程组(78.12%)的总有效率更高;治疗后,短病程组左室射血分数(LVEF)水平高于长病程组,室间隔厚度(IVS)、左心收缩末期内径(LVESD)、左室后壁厚度(LVPW)、左心舒张末期内径(LVEDD)水平低于长病程组;治疗后,短病程组身体、情绪和其他领域评分及明尼苏达心衰生活质量量表(MLHFQ)均低于长病程组。短病程组随访12个月的无事件生存率为98.44%(63/64)较长病程组89.06%(57/64)更高。结论:相比病程3年以上慢性心衰伴高血压患者,沙库巴曲缬沙坦钠能够显著提高病程3年及以下的慢性心衰伴高血压患者临床疗效,且显著改善患者心室重构、生活质量及随访12个月的无事件生存状况。

Objective To investigate the effects of sacubatrovalsartan sodium on chronic heart failure with hypertension and ventricular remodeling in patients with different courses of disease.Methods A total of 128 patients with chronic heart failure and hypertension admitted to our hospital from October 2021 to October 2022 were prospectively selected and divided into long course group and short course group according to the different course of disease,64 cases each.The long-term group consists of patients with chronic heart failure and hypertension who have a disease course of more than 3 years;The short course group refers to patients with chronic heart failure and hypertension who have a course of 3 years or less.Both groups of patients were treated with Sacubatrovalsartan sodium.Compare the clinical outcomes,ventricular remodeling,and quality of life between the two groups of patients before and after treatment,as well as the event free survival status at a follow-up of 12 months.Results The total effective rate in the short course group(98.44%)and the long course group(78.12%)was significantly higher.After treatment,the level of left ventricular ejection fraction(LVEF)in the short course group was higher than that in the long course group,while the levels of interventricular septum thickness(IVS),left ventricular end systolic diameter(LVSD),left ventricular posterior wall thickness(LVPW)and left ventricular end diastolic diameter(LVEDD)were lower than those in the long course group.After treatment,the scores of physical,emotional and other fields and the Minnesota Heart Failure Quality of Life Scale(MLHFQ)in the short course group were lower than those in the long course group.The 12-month event-free survival rate in the short course group(98.44%)was higher than those in the long course group(89.06%).Conclusion Compared with patients with chronic heart failure and hypertension with a course of more than 3 years,Sakubactril valsartan sodium significantly improved the clinical outcome of patients with chronic heart failure and hypertension with a course of less than 3 years,and significantly improved ventricular remodeling,quality of life and event-free survival at 12 months follow-up.